Modulation of GABA- and Glycine-Activated Ionic Currents with Semax in Isolated Cerebral Neurons

[1]  A. Ottani,et al.  Multiple beneficial effects of melanocortin MC4 receptor agonists in experimental neurodegenerative disorders: Therapeutic perspectives , 2017, Progress in Neurobiology.

[2]  F. Saitow,et al.  Differential Modulation of GABAA Receptors Underlies Postsynaptic Depolarization- and Purinoceptor-Mediated Enhancement of Cerebellar Inhibitory Transmission: A Non-Stationary Fluctuation Analysis Study , 2016, PloS one.

[3]  Kristina D. Micheva,et al.  Enhanced phasic GABA inhibition during the repair phase of stroke: a novel therapeutic target , 2015, Brain : a journal of neurology.

[4]  I. Módy,et al.  Reducing excessive GABA-mediated tonic inhibition promotes functional recovery after stroke. , 2010, Nature.

[5]  Tian-Le Xu,et al.  Glycine and glycine receptor signaling in hippocampal neurons: Diversity, function and regulation , 2010, Progress in Neurobiology.

[6]  R. Cone.  Anatomy and regulation of the central melanocortin system , 2005, Nature Neuroscience.

[7]  J. M. Lipton,et al.  Targeting Melanocortin Receptors as a Novel Strategy to Control Inflammation , 2004, Pharmacological Reviews.

[8]  E. Tietz,et al.  Role of protein kinase A in GABAA receptor dysfunction in CA1 pyramidal cells following chronic benzodiazepine treatment , 2003, Journal of neurochemistry.

[9]  I. Módy,et al.  Differential regulation of synaptic GABAA receptors by cAMP‐dependent protein kinase in mouse cerebellar and olfactory bulb neurones , 1999, The Journal of physiology.

[10]  S. Moss,et al.  Adjacent phosphorylation sites on GABAA receptor β subunits determine regulation by cAMP-dependent protein kinase , 1998, Nature Neuroscience.

[11]  V. I. Skvortsova,et al.  [Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency]. , 2005, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[12]  Skvortsova Vi,et al.  Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency , 2005 .

[13]  A. Kaplan,et al.  Nootropic analogue of adrenocorticotropin 4-10-semax (the experience of design and investigation over 15 years) , 1997 .

[14]  V. I. Skvortsova,et al.  [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. , 1997, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

[15]  Skvortsova Vi,et al.  Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) , 1997 .